Long-lived plasma cells, which produce autoantibodies in diseases such as systemic lupus erythematosus (SLE), are an as yet unexplored therapeutic target in such antibody-mediated disorders.

Plasma cells (PCs) are the terminal differentiation stage of activated B cells and serve as crucial effector cells in humoral immunity. While PCs have ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

Antibodies are produced by B lymphocytes through a process called clonal selection. When a B cell encounters an antigen that matches its specific receptor, it becomes activated and proliferates, ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

This article explores how broadly neutralizing antibodies are being researched, not only for their potential in the ...

Medically reviewed by Lindsay Cook, PharmD Multiple myeloma (also referred to as myeloma) is a type of rare, incurable cancer ...

These results were similar to those of the control antibody. Plasma cells at the end stage of B cell differentiation are organized using Beacon ®, and memory B cells with antibodies expressed on ...

Deposits of amyloid protein form more quickly than the body can break them down. Plasma cells produce antibodies, which form part of the immune system and help fight off infections ...